Interferon alpha-2b/interferon gamma - Heber Biotech

Drug Profile

Interferon alpha-2b/interferon gamma - Heber Biotech

Alternative Names: CIGB-128; CIGB-128-A; HeberFERON; HeberPAG; Interferon-alpha-2b/interferon-gamma; Interferon-gamma/interferon-alpha-2b

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Basal cell cancer
  • Phase I Mycosis fungoides
  • Preclinical Brain cancer

Most Recent Events

  • 09 Jan 2017 Center for Genetic Engineering and Biotechnology plans a phase I/II trial in Renal cell carcinoma in Cuba (RPCEC00000229)
  • 04 Feb 2016 This programme is still active
  • 04 Feb 2016 Interferon alpha-2b/interferon gamma - Heber Biotech is available for licensing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top